(7-Mercapto-indan-4-yloxy)-acetic acid methyl ester | 600176-68-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (7-Mercapto-indan-4-yloxy)-acetic acid methyl ester
• 英文别名: methyl 2-[(7-sulfanyl-2,3-dihydro-1H-inden-4-yl)oxy]acetate
• CAS: 600176-68-9
• 化学式: C₁₂H₁₄O₃S
• 分子量: 238.307
• InChiKey: SYQAXUAVRVDBBM-UHFFFAOYSA-N

物化性质

• 沸点：
  387.5±42.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  36.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (7-Mercapto-indan-4-yloxy)-acetic acid methyl ester 在 bis-triphenylphosphine-palladium(II) chloride 、 1,1'-双(二苯基膦)二茂铁 、 tris-(dibenzylideneacetone)dipalladium(0) 、 二(三叔丁基膦)钯 copper(l) iodide 、 三乙胺 、 二异丙胺 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 为溶剂， 反应 20.5h， 生成 [7-[2,6-bis-(4-chloro-phenylethynyl)-pyridine-4-ylsulfanyl]-indan-4-yloxy]-acetic acid methyl ester
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS, THEIR PREPARATION AND USE
  [FR] NOUVEAUX COMPOSES, LEUR PREPARATION ET LEUR UTILISATION

  摘要：

  通用公式（I）的新化合物，其中变量如权利要求书中所定义的，这些化合物的用途作为药物组合物，包含这些化合物的药物组合物以及使用这些化合物和组合物进行治疗的方法。这些化合物在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中具有用途，特别是PPARδ亚型，即1型糖尿病、2型糖尿病、血脂异常、X综合症（包括代谢综合症，即糖耐量受损、胰岛素抵抗、高三酸甘油酯血症和/或肥胖）、心血管疾病（包括动脉粥样硬化）和高胆固醇血症的治疗中有用。

  公开号：

  WO2005105726A1
• 作为产物：
  描述：

  7-羟基-2,3-二氢-1H-茚-4-基硫氰酸酯 在 1,4-dithio-erythritol 、 caesium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 4.0h， 生成 (7-Mercapto-indan-4-yloxy)-acetic acid methyl ester
  参考文献：
  名称：

  Design of a partial PPARδ agonist

  摘要：

  Structure based ligand design was used in order to design a partial agonist for the PPAR delta receptor. The maximum activation in the transactivation assay was reduced from 87% to 39%. The crystal structure of the ligand binding domain of the PPAR delta receptor in complex with compound 2 was determined in order to understand the structural changes which gave rise to the decrease in maximum activation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.079

文献信息

• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20030207916A1

  公开（公告）日：2003-11-06

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

  这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。
• Novel compounds, their preparation and use
  申请人：Havranek Miroslav

  公开号：US20090209588A1

  公开（公告）日：2009-08-20

  Novel compounds of the general formula (I), in which the variables are as defined in claim 1 , the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.

  通用公式(I)的新化合物，其中变量的定义如权利要求1中所述，这些化合物作为药物组成物的用途，包含这些化合物的药物组成物以及使用这些化合物和组成物进行治疗的方法。这些化合物在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型，即1型糖尿病、2型糖尿病、血脂异常、X综合征（包括代谢综合征，即糖耐量受损、胰岛素抵抗、高三酰甘油血症和/或肥胖）、心血管疾病（包括动脉粥样硬化）和高胆固醇血症。
• Compounds that modulate PPAR activity and methods for their preparation
  申请人：——

  公开号：US20030225158A1

  公开（公告）日：2003-12-04

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

  该发明揭示了可以改变PPAR活性的化合物。该发明还揭示了这些化合物的药用可接受盐、含有这些化合物或其盐的药用可接受组合物，以及将它们用作治疗或预防哺乳动物的失脂血症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉粥样硬化、高甘油三酯血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。
• COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION
  申请人：Auerbach J. Bruce

  公开号：US20050153996A1

  公开（公告）日：2005-07-14

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

  本发明揭示了能够改变PPAR活性的化合物。本发明还揭示了这些化合物的药学上可接受的盐，包含这些化合物或其盐的药学上可接受的组合物，以及将它们用作治疗或预防哺乳动物的失脂症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉硬化、高三酰甘油血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。
• Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) δ agonists
  作者：Larry D. Bratton、Gary F. Filzen、Andrew Geyer、Jennifer K. Hoffman、Gina Lu、Jim Pulaski、Bharat K. Trivedi、Paul C. Unangst、Xiangyang Xu

  DOI：10.1016/j.bmcl.2007.04.046

  日期：2007.7

  A series of 1,4-benzyloxybenzylsulfanylaryl carboxylic acids were prepared and their activities for PPAR receptor subtypes (alpha, beta, and gamma) with potential indications for the treatment of dyslipidemia were investigated. Analog 13a displayed the greatest binding affinity (IC50 = 10 nM) and selectivity (120-fold) for PPAR delta over PPAR alpha. Many of the analogs investigated were found to be highly selective for PPAR delta and were dependent on the point of attachment of the substituent. In the 1,4-series, analog 28e was found to be the most potent (IC50 = 1.7 nM) and selective (> 1000-fold) compound for PPAR delta. None of the compounds tested showed appreciable binding affinity for PPAR gamma. (c) 2007 Elsevier Ltd. All rights reserved.